研究风湿免疫病患者应用益赛普治疗临床疗效.docVIP

研究风湿免疫病患者应用益赛普治疗临床疗效 　　【摘要】 目的 探究风湿免疫病患者应用生物制剂（益赛普）治疗的临床疗效。方法 60例风湿免疫病患者， 根据入院先后顺序分为观察组与对照组， 各30例。对照组给予常规治疗， 观察组给予生物制剂治疗， 对两组患者治疗前后的临床症状评分以及临床治疗效果进行综合评价比较。结果 治疗前， 两组患者发热、疼痛、肌肉乏力评分比较差异无统计学意义（P0.05）；治疗后， 两组患者发热、疼痛、肌肉乏力评分均较治疗前改善， 且观察组明显优于对照组， 差异有统计学意义（P0.05）。治疗后， 观察组总有效率为93.3%， 显著高于对照组的70.0%， 差异具有统计学意义（P0.05）。结论 生物制剂治疗风湿免疫病患者， 能够促进患者临床症状改善， 效果显著， 值得推广应用。 　　【关键词】 风湿免疫病；生物制剂；临床症状；治疗效果 　　DOI：10.14163/j.cnki.11-5547/r.2018.14.056 　　Study on clinical efficacy of Yisaipu in the treatment of rheumatic immune disease patients PAN Tong， ZHU An-li， GUO Fei， et al. Department of Rheumatism Immunity， Liaocheng Second People’s Hospital， Liaocheng 252600， China 　　【Abstract】 Objective To investigate the clinical efficacy of biological agents （Yipusai） in the treatment of rheumatic immune disease patients. Methods A total of 60 rheumatic immune disease patients were divided by admission order into observation group and control group， with 30 cases in each group. The control group received conventional therapy， and the observation group received biological agents for treatment. Comprehensive evaluation and comparison were made on clinical symptom score before and after treatment and clinical treatment effect between the two groups. Results Before treatment， both groups had no statistically significant difference in fever， pain， muscle weakness score （P0.05）. After treatment， both groups had improved fever， pain， muscle weakness score than before treatment， and the observation group was obviously better than the control group. Their difference was statistically significant （P0.05）. After treatment， the observation group had obviously higher total effective rate as 93.3% than 70.0% in the control group， and the difference was statistically significant （P0.05）. Conclusion Biological agents shows remarkable effect for patients with rheumatic immune disease， and it can promote the improvement of clinical symptoms. It is worthy of promotion and application. 　　【Key words】 Rheumatic imm